Zhu Yeli, Fan Jingxian, Zhu Xiying, Li Wei, Zhang Zhaoyong, Zheng Hui, Zhou Zhihua, Meng Lingchao, Zhang Ruxu, Jiang Haishan
Department of Neurology, Southern Medical University Nanfang Hospital, Southern Medical University, Guangzhou, China.
Department of Neurology, Central South University Third Xiangya Hospital, Central South University, Changsha, China.
Orphanet J Rare Dis. 2025 Apr 28;20(1):202. doi: 10.1186/s13023-025-03733-0.
Our study aimed to report the clinical features and epidemiological characteristics of hereditary transthyretin amyloidosis-polyneuropathy(ATTRv-PN) with TTR Ala97Ser(p.Ala117Ser) mutation from South Mainland China.
We identified 21 patients from 20 families diagnosed with Ala97Ser ATTRv-PN based on strict clinical and electrophysiological criteria from three centers. Clinical and laboratory data were retrospectively retrieved for analysis.
A gender imbalance was noted with a male-to-female ratio of 18:3. All patients showed late onset, with the age of onset at 56.5 ± 7.2 years. The predominant initial symptom, reported by 15 patients (71.4%), was numbness. Paraesthesia was present in all patients. Eighteen patients (85.7%) had autonomic dysfunction. Cardiac, renal, and ocular dysfunctions were noted in 17 (80.9%), 4(19.0%), and 4(19.0%) patients, respectively. Nerve conduction studies have shown axonal-type sensorimotor polyneuropathy. The decline in sensory nerve action potentials was more noticeable than in compound muscle action potentials. The nerve damage present in the lower limbs was more severe than that in the upper limbs. Nerve biopsy revealed positive Congo red staining in 11/15 patients (73.3%).
ATTRv-PN appears relatively rare in South Mainland China, with our study providing the largest cohort of Ala97Ser mutation cases to date. We found a significant founder effect by combining the clinical and demographic characteristics. That helps us understand the gene's transmission pathway and lays the foundation for carrier screening and tertiary prevention and control. We also propose a new scoring model and demonstrate that this model allows the profiling of different genotypes of ATTRv-PN, facilitating early clinical detection and diagnosis.
我们的研究旨在报告中国华南地区携带甲状腺素运载蛋白(TTR)Ala97Ser(p.Ala117Ser)突变的遗传性转甲状腺素蛋白淀粉样变多发性神经病(ATTRv-PN)的临床特征和流行病学特征。
我们从三个中心严格按照临床和电生理标准,确定了20个家庭中的21例诊断为Ala97Ser ATTRv-PN的患者。回顾性收集临床和实验室数据进行分析。
发现性别失衡,男女比例为18:3。所有患者均为晚发型,发病年龄为56.5±7.2岁。15例患者(71.4%)报告的主要初始症状为麻木。所有患者均有感觉异常。18例患者(85.7%)有自主神经功能障碍。分别有17例(80.9%)、4例(19.0%)和4例(19.0%)患者出现心脏、肾脏和眼部功能障碍。神经传导研究显示为轴索性感觉运动性多发性神经病。感觉神经动作电位的下降比复合肌肉动作电位更明显。下肢的神经损伤比上肢更严重。神经活检显示11/15例患者(73.3%)刚果红染色阳性。
ATTRv-PN在中国华南地区似乎相对罕见,我们的研究提供了迄今为止最大的Ala97Ser突变病例队列。通过结合临床和人口统计学特征,我们发现了显著的奠基者效应。这有助于我们了解该基因的传播途径,并为携带者筛查以及三级预防和控制奠定基础。我们还提出了一种新的评分模型,并证明该模型能够对ATTRv-PN的不同基因型进行分析,有助于早期临床检测和诊断。